A Phase 1 interventional study of Elacestrant in Advanced ER+, HER2-Negative Breast Cancer, sponsored by Stemline Therapeutics, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-18.
Sponsored by Stemline Therapeutics, Inc. (part of Menarini Group) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing elacestrant in Breast Neoplasms — 15 open to participants now, 18 under way, 3 of them phase 3. elacestrant · Breast Neoplasms.
Among the 24 studies testing elacestrant in Breast Neoplasms, this one is the 16th largest by enrollment, is the only one that started in 2015, is one of 4 in phase 1, and was the 1st registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →15 of the 24 studies testing elacestrant in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Stemline Therapeutics, Inc. · Sites in Japan
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+ · Women only
European Institute of Oncology · Sites in Italy
Ages 18+
Women's Cancer Study Group GmbH · Sites in Germany
Ages 18+
Kristina A. Fanucci · Sites in United States
Ages 18+
By country, each count listing its studies:
elacestrant: first FDA approval 2023 (ORSERDU), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, elacestrant is the treatment under test here. Read study by study →
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 16 · Phase 3 4
First in 2015; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 72 across the 24 interventional studies. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 24 have an industry lead sponsor. The 10 most frequent:
This study is registered under Stemline Therapeutics, Inc., one of the names counted as Menarini Group. Under that name alone:
Stemline Therapeutics, Inc. is the lead sponsor of 23 studies on the registry; 7 are open to participants now.
14 studies in Breast Neoplasms by Menarini Group: 4 open now, 8 under way, 1 of them phase 3. Of 6 finished, 2 (33%) have results posted.
Among the 14 studies in Breast Neoplasms by Menarini Group, this one is the 9th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2015, is one of 6 in phase 1, and was the 1st registered.
Menarini Group’s Breast Neoplasms studies by the year they started, since 2015.
7 of the studies testing elacestrant in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05596409Stemline Therapeutics, Inc.ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study | 2026-11 |
| NCT05386108Stemline Therapeutics, Inc.Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | 2026-12 |
| NCT05982093SOLTI Breast Cancer Research GroupElacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer | 2026-12 |
| NCT05563220Stemline Therapeutics, Inc.Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | 2026-12-27 |
| NCT07159451Gustave Roussy, Cancer Campus, Grand ParisA Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer | 2027-01-29 |
Add all 7 to your calendar (.ics) → With an account.
Among the 24 studies testing elacestrant in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Menarini Group’s 14 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability and preliminary efficacy of elacestrant (RAD1901) in patients with advanced ER+, HER2-negative breast cancer.
The primary objective is to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of elacestrant in patients with advanced ER+HER2-negative breast cancer.
The secondary objectives of this study are:
Key Inclusion Criteria:
Note: This list is not complete. Further inclusion criteria is provided in the protocol synopsis.
Key Exclusion Criteria:
Prior anticancer or drug treatment within the following windows:
Note: This list is not complete. Further exclusion criteria is provided in the protocol synopsis.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A, Dose Escalation: Patients will be assigned sequentially to escalating doses of elacestrant. Part B, Safety Expansion: Once the MTD has been identified and/or a RP2D has been selected, additional patients will be enrolled to further evaluate the safety, tolerability and preliminary efficacy of the RP2D. Part C, Tablet Introduction: A cohort of patients will be enrolled to evaluate the safety, tolerability, and PK of a tablet dosage form at 400 mg QD. Part D, Dose Expansion: A cohort of patients will be enrolled to evaluate the safety, tolerability, PK and preliminary anti-tumor effect of elacestrant in tablet dosage form at 400 mg QD PO in a group of patients with a more homogeneous prior treatment history
Drug: Elacestrant
Dose Limiting Toxicities (DLT)
To determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of Elacestrant (RAD1901), the incidence of Dose Limiting toxicities (DLTs) will be assessed.
Time frame: The first 28 days of treatment.
Safety and Tolerability of Elacestrant (RAD1901)
Safety and tolerability will be assessed in terms of adverse events, serious adverse events, ECG, physical examination, vital signs, and laboratory values.
Time frame: Up to 30 days after the end of treatment.
Pharmacokinetics of Elacestrant (RAD1901)
Plasma concentrations of RAD1901 will be assessed at predefined intervals
Time frame: Every 28 days
Anti-Tumor Effect of Elacestrant (RAD1901)
Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines.
Time frame: Every 8 weeks
Ran from Jan 2015 to primary completion in Sep 2019, 56 months.
Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 56 months is above that.
Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Elacestrant